Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice

Journal of Natural Medicines

Volumn 67, Issue 1, 2013, Pages 107-112

  Bisong, Sunday Agba ^a,b   Brown, Richard Earl ^b   Osim, Eme Effiom ^a  

^a UNIVERSITY OF CALABAR   (Nigeria)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Chlorpromazine; Extrapyramidal effects; Rauwolfia vomitoria; Reserpine

Indexed keywords

C8138 5G; CHLORPROMAZINE; NEUROLEPTIC AGENT; PLANT EXTRACT; R 0875 1G; RAUWOLFIA VOMITORIA EXTRACT; RESERPINE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARK; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; LOCOMOTION; MALE; MASTICATION; MOTOR COORDINATION; MOUSE; NONHUMAN; OPEN FIELD TEST; PLANT ROOT; PSYCHOSIS; RAUWOLFIA; RAUWOLFIA VOMITORIA; TREATMENT OUTCOME; TREMOR; VACUOUS CHEWING MOVEMENT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; MALE; MICE; MOTOR ACTIVITY; PLANT BARK; PLANT EXTRACTS; PLANT ROOTS; PSYCHOTIC DISORDERS; RAUWOLFIA; RESERPINE;

EID: 84871640823     PISSN: 13403443     EISSN: 18610293     Source Type: Journal    
DOI: 10.1007/s11418-012-0657-8     Document Type: Article

References (35)

1. Swett C Jr, Cole JO, Shapiro S, Slone D (1977) Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis. Arch Gen Psychiatry 34(8):942-943 (Pubitemid 8163836)
2. Patterson BD, Swingler D, Willows S (2005) Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res 76:89-97 (Pubitemid 40824564)
3. Bishnoi M, Kumar A, Chopra K, Kulkarni SK (2007) Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Indian J Exp Biol 45(2):175-179
4. Llorca PM, Chereau I, Bayle FJ, Lancon C (2002) Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 17(3):129-138 (Pubitemid 34800019)
5. Wang PS, Schneeweiss S, Avorn J (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353(22):2335-2341 (Pubitemid 41713745)
6. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-77
7. Hardman JG, Limbird LE, Gilman AG (2001) Drugs and the treatment of psychiatric disorders: the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York
8. Remington G (2003) Understanding antipsychotic "atypicality": A clinical and pharmacological moving target. J Psychiatry Neurosci 28(4):275-284 (Pubitemid 37153435)
9. Peirre JM (2005) Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28:191-208 (Pubitemid 40364887)
10. Chong MY, Tan CH, Fujii S, Yang S, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N (2004) Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 58:61-67 (Pubitemid 38200373)
11. World Health Organization (WHO) (2003). Essential medicines, 13th edn. WHO model list. http://www.who.int/hac/techguidance/pht/essentialmed/en. Retrieved 23 Oct 2007
12. Makanjuola ROA (1987) Yoruba traditional healer in psychiatry. Healers' concept of the nature and aetiology of mental disorders. Afr J Med Med Sci 16:53-59
13. Gureje O, Acha RA, Odejide OA (1995) Pathways to psychiatric care in Ibadan, Nigeria. Trop Geogr Med 47:125-129
14. Kanba S, Yamada K, Mizushima H, Asai M (1998) Use of herbal medicine for treating psychiatric disorders in Japan. Psychiatry Clin Neurosci 52:331-333
15. Unützer J, Klap R, Sturm R, Young AS, Marmon T, Shatkin J, Wells KB (2000) Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 157:1851-1857
16. Akpanabiatu MI, Umoh IB, Eyong EU (2006) Influence of Rauwolfia vomitoria root bark on cardiac enzymes of normal Wistar albino rats. Recent Progr Med Plants 14:273-278
17. Kweifio-Okai G, Bird D, Field B, Ambrose R, Carol AR, Smith P, Valdes R (1995) Anti-inflammatory activity of a Ghanaian antiarthritic herbal preparation: III. J Ethnopharmacol 46:7-15
18. Amole OO, Onabanjo AO (1999) Reserpine: the effect and uses of Rauwolfia vomitoria. J Chemother 3:45-47
19. Campbell JIA, Mortensen A, Molgaard P (2006) Tissue lipid lowering-effect of a traditional Nigerian anti-diabetic infusion of Rauwolfia vomitoria foliage and Citrus aurantium fruit. J Ethnopharmacol 104:379-386 (Pubitemid 43361699)
20. Bemis DL, Capodice JL, Gorroocurn P, Katz AE, Buttyan R (2006) Anti-prostate cancer activity of β-carboline alkaloid enriched extract from Rauwolfia vomitoria. Int J Oncol 29:1065-1073
21. Bisong SA, Akpanabiatu MI, Osim EE (2006) The effect of crude root extract of Rauwolfia vomitoria on learning and memory in mice. Recent Progr Med Plants 22:153-162
22. Amole OO, Yemitan OK, Oshikoya KA (2009) Anticonvulsant activity of Rauvolfia Vomitoria (Afzel). Afr J Pharmacy Pharmacol 3(6):319-322
23. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G (2005) History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17(3):113-135 (Pubitemid 41176798)
24. Aminoff MJ (2004) Pharmacologic management of Parkinsonism and other movement disorders. In: Katzung BG (ed) Basic and clinical pharmacology, 9th edn. McGraw-Hill, Singapore, pp 447-461
25. Giachetti A, Shore PA (1978) The reserpine receptor. Life Sci 23(2):89-92 (Pubitemid 8399959)
26. Isharwel S, Gupta S (2006) Rustmon Jal Vakil. His contributions to cardiology. Texax Heart Inst J 33(2):161-170 (Pubitemid 44299847)
27. Klyushnichenko VE, Yakimov SA, Tuzova TP, Syagailo YV, Kuzovkina IN, Wulfson AN, Miroshnikov AI (1995) Determination of indole alkaloids from R. serpentina and R. vomitoria by high-performance liquid chromatography and high-performance thin-layer chromatography. J Chromatogr 704:357-362
28. Brown RE, Corey SC, Moore AK (1999) Differences in measures of exploration and fear in MHC-congenic C57BL/6J and B6-H-2K mice. Behav Genet 26:263-271
29. Caston J, Devulder B, Jouen F, Lalonde R (1999) Role of an enriched environment on the restoration of behavioral deficits in Lurcher mutant mice. Dev Psychobiol 35:291-303
30. Seibt KJ, Oliveira Rda L, Zimmermann FF, Capiotti KM, Bogo MR, Ghisleni G, Bonan CD (2010) Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio). Behav Brain Res. 25;214(2):417-422
31. Naidu PS, Kulkarni SK (2002) Reversal of reserpine-induced vacuous chewing movements by ethanol: possible GABA-A receptor modulation. Brain Pharmacol 1:189-195
32. Casey DE (2000) Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 61:5-9 (Pubitemid 30158596)
33. Andreassen OA, Jorgessen HA (2000) Neurotoxicity associated with neuroleptic induced oral dyskinesias in rats implications for tardive dyskinesia? Prog Neurobiol 61:525-541 (Pubitemid 30169057)
34. Miwa H (2007) Rodent models of tremor. Cerebellum 6(1):66-72 (Pubitemid 46410668)
35. Oyewole OI, Massaquoi HO (2008) Oral administration of Rauwolfia vomitoria extract has no untoward effect on kidney and liver functions in rats. Afr J Biotechnol 7(10):1577-1580 (Pubitemid 351776183)